Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Seasonal Allergic Rhinitis
NCT07091357Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1819 in seasonal allergic rhinitis (SAR), sponsored by Hengrui Therapeutics. Started Aug 2025; status: completed.
02
Drugs
SHR-1819
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07091357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091357.